{"filing":{"accession_number":"0001104659-26-078848","cik":"0001819411","ticker":"GANX","company_name":"Gain Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"tm2619336d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1819411/000110465926078848/tm2619336d1_8k.htm"},"events":[{"id":14655,"run_id":13057,"accession_number":"0001104659-26-078848","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The disclosure announces FDA authorization of an Investigational New Drug (IND) application for GT-02287, enabling the company to initiate Phase 2 clinical development in Parkinson's disease. This is a material regulatory milestone in the drug development pipeline that would affect a reasonable investor's assessment of the company's progress and prospects, but does not fit the specific categories of earnings, M\u0026A, impairment, litigation, or other named event types. It is clearly an operational/strategic business milestone.","company_name":"Gain Therapeutics, Inc.","ticker":"GANX","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":12148,"accession_number":"0001104659-26-078848","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces FDA authorization of an Investigational New Drug (IND) application for GT-02287, enabling the company to initiate Phase 2 clinical development in Parkinson's disease. This is a material regulatory milestone in the drug development pipeline that would affect a reasonable investor's assessment of the company's progress and prospects, but does not fit the specific categories of earnings, M\u0026A, impairment, litigation, or other named event types. It is clearly an operational/strategic business milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:23:36.445913+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12148,"accession_number":"0001104659-26-078848","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces FDA authorization of an Investigational New Drug (IND) application for GT-02287, enabling the company to initiate Phase 2 clinical development in Parkinson's disease. This is a material regulatory milestone in the drug development pipeline that would affect a reasonable investor's assessment of the company's progress and prospects, but does not fit the specific categories of earnings, M\u0026A, impairment, litigation, or other named event types. It is clearly an operational/strategic business milestone.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:23:36.445913+00:00","company_name":"Gain Therapeutics, Inc.","ticker":"GANX","filing_date":"2026-06-29"}]}